Novel Methylation Biomarkers Predict Tumour Recurrence/Progression at Initial Diagnosis of High-risk Non-Muscle Invasive Bladder Cancer
BAUS ePoster online library. Bryan R. 06/24/19; 259509; P2-5 Disclosure(s)(s): Nil
Rik Bryan
Rik Bryan
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)

High-risk non-muscle invasive bladder cancer (HR-NMIBC) is a clinically unpredictable disease. Despite risk estimation tools, many patients are undertreated with intra-vesical therapies alone, whereas others may be over-treated with early radical surgery.
DNA methylation is reported as predictive of tumour/patient outcomes in numerous solid organ and haematological malignancies; however, there are few reports in HR-NMIBC and none using genome-wide array assessment. We therefore sought to identify novel DNA methylation markers of HR-NMIBC that predict tumour behaviour at initial diagnosis to help guide patient management.

21 primary initial diagnosis HR-NMIBC tumours (from the Birmingham BCPP cohort) were analysed by Illumina HumanMethylation450 BeadChip arrays, and subsequently bisulphite Pyrosequencing™. Seven had not recurred at one year after resection and 14 had recurred and/or progressed, despite intra-vesical BCG. A further independent cohort of 32 HR-NMIBC tumours (17 no recurrence and 15 recurrence and/or progression despite BCG) were also assessed by bisulphite Pyrosequencing™.


Array analyses identified 206 CpG loci that segregated non-recurrent HR-NMIBC tumours from clinically more aggressive recurrence/progression tumours. Pyrosequencing™ validation across the 53 tumours showed hypermethylation of CpG cg11850659 and hypomethylation of CpG cg01149192 in combination predicted HR-NMIBC recurrence and/or progression within one year of diagnosis with 83% sensitivity, 79% specificity, and 83% positive and 79% negative predictive values.

This is the first genome-wide DNA methylation analysis of a unique HR-NMIBC tumour cohort encompassing known one-year clinical outcomes. Our analyses identified potential novel epigenetic markers that could help guide individual patient management in this clinically unpredictable disease.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings